2026 Aussie Equities Day

Doug Hunt is the former Chief Executive of Europcar Asia Pacific and former Regional Director Asia Pacific for Europcar International, responsible for 31 countries in the APAC region. He has extensive international experience in international franchising and licensing and also brings extensive experience in the application and integration of alternative energy solutions, with seven years experience in the renewables industry in the USA and Australia.

Dr Julian Chick is an experienced healthcare executive with over 20 years’ experience in senior management including in ASX listed companies Avexa and Admedus. His roles have included Chief Executive Officer, COO and Head of Business Development, as well as running early and late stage R&D projects and launching medical devices into the global markets. Dr Chick’s experience includes developing and obtaining FDA USA clearance for four tissue based medical devices. Dr Chick while COO at Admedus Ltd was involved in the R&D development, regulatory approval and launch of several tissue products in North America, Europe and Asia. He has eight years’ investment banker experience and has also held a role as an analyst reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists. Julian has a PhD in Muscle Physiology.

Ben Hutt is CEO and Managing Director of Janus Electric, leading the commercialisation of zero-emissions solutions for heavy transport. With more than 20 years’ experience across energy, technology and capital markets, Ben has a strong track record scaling high-growth businesses. He previously served as CEO of Evergen, where he grew the company from startup to a leading energy SaaS platform, culminating in its acquisition in 2023. He has also helped build 200+ startups at Slingshot Accelerator, led another SAAS business through an international expansion and an ASX listing and held senior roles at Macquarie Group. Ben brings deep expertise in the energy transition and is focused on accelerating practical, scalable decarbonisation across freight networks.

Mr Brian Leedman is a biotechnology entrepreneur having co-founded seven healthcare companies on the ASX. Digital respiratory diagnostics company, ResApp Health Limited, in which he served as the executive director, was acquired by Pfizer in 2022. Mr Leedman also served as Chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and Ausbiotech (WA). He was a Director of Alcidion Corporation Limited, Oncosil Medical Limited, Respiri Limited and a founder of Imugene Limited. Previously, he spent a decade as the vice president of investor relations at ASX, Nasdaq and Frankfurt listed, pSivida Corporation (renamed Eyepoint Therapeutics) and held senior marketing positions at Westpac Banking Corporation and Ernst & Young. He holds a B.Econs and an MBA from the University of Western Australia.

Dr Kurt Sales is a pharmaceutical executive and translational scientist with more than 25 years of experience across drug discovery, preclinical development, clinical research, regulated bioanalysis, and biotechnology operations. He currently serves as Chief Operating Officer of Myopharm Limited, where he leads operational execution and clinical development activities for the company’s metabolic and inflammatory disease pipeline, including the lead asset TriGlytza®.
Dr Sales has held senior scientific leadership roles across academia, biotechnology, and contract research organisations, including Chief Scientific Officer positions supporting first-in-human and global clinical programs. He has authored more than 50 peer-reviewed publications and is internationally recognised for his expertise in inflammatory signalling, regulated bioanalysis and translational medicine.
His experience spans the full drug development continuum, from target identification through clinical trial support and regulatory strategy, with a strong focus on therapies addressing unmet needs in chronic inflammatory disease.

Peter Molloy trained as a microbiologist and biochemist and then built a successful marketing and general management career in the international pharmaceutical industry. At Faulding (Aust) he was General Manager of the Medical Products Division and then at Pharmacia (Pfizer), he was Managing Director of Australia/NZ operations and later International Vice President for Strategic Marketing. During his pharmaceutical career, he launched 23 new products and executed 40 international licensing or distribution deals. Subsequently, he was CEO of four biotech companies in US and Australia, including two ASX-listed firms. He served as CEO of antiviral drug development company, Biota Holdings Limited (ASX: BTA) from 2002 to 2005, and he was founding CEO of Race Oncology from 2016 to 2020. He founded Firebrick Pharma in 2012 and moved to full-time CEO and Chairman in 2020, taking the company public in 2022 (ASX: FRE). He is an inventor on all the Firebrick patents. He completed his PhD in biotechnology business in 2019 with the title: “Value creation and investor performance of the Australian drug development biotechnology sector”; he has published multiple papers and been an invited speaker at industry fora on the topic of value creation in the biotech sector.

James Durrant brings over 15 years of experience spanning mine operations, project development, and sustainable resource management to the company. With a strong background in managing emerging market mineral resource projects, James provides strategic leadership for EAU Mining’s operations. His expertise in pre-feasibility and feasibility studies, stakeholder engagement, and navigating complex geopolitical environments aligns perfectly with EAU Mining’s focus on sustainable and impactful mining initiatives.

James’s prior roles, including Managing Director and CEO of RareX Ltd, showcase his ability to optimize asset portfolios and expand operations through targeted acquisitions and advanced technical strategies. His tenure at Danakali Limited saw him lead critical feasibility and socio-environmental workstreams for the Colluli Potash Project in Eritrea, East Africa, further demonstrating his capability in delivering large-scale projects in challenging environments. With deep operational knowledge from his time at BHP Billiton and project leadership roles in Africa and Australia, James combines technical proficiency with visionary leadership to drive sustainable growth at EAU Lithium.

Mr Williams holds both Bachelor of Arts and Law Degrees from the University of Queensland and practised as a corporate, commercial and mining lawyer with Brisbane legal firm HopgoodGanim for 17 years, with the last few of those years as an equity partner of the firm. He then worked as General Counsel to Mitsui Coal’s worldwide coal operations for several years until 2013, when he joined Chinalco Yunnan Copper Resources Limited (the precursor to AuKing Mining Limited) in 2013 as Managing Director.

Over the course of a career spanning more than 35 years, Mr Williams has developed a commercial skillset that is well established for the operation of exploration companies listed on the ASX – spanning experiences including:

• negotiation and preparation of commercial arrangements in the exploration and mining sector across five continents;
• engagement with and participation in management of exploration and mining companies – big and small;
• understanding and co-operating with the requirements of local communities and stakeholders in various jurisdictions around the world;
• overseeing the development and implementation of corporate governance policies and procedures;
• engagement with a wide range of investors, corporate advisors and financiers, institutional firms; and
• public and investor relations activities with shareholders and the broader investment community.

Since July 2018, Kate Quirke has been the Group Managing Director and Chief Executive Officer of the Alcidion Group, a company dedicated to providing smart technology to the health sector. Kate leads the business globally with current focus on Australia, New Zealand and the United Kingdom with a goal of developing mutually beneficial relationships with customers, partners and investors. Kate has 25+ years of digital health sector experience and has been involved in large procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes leading management roles at large healthcare software firms where she has driven strategic product direction. She strongly believes that the astute application of information technology will support the transformation of healthcare delivery worldwide.

Kate is a Non-Executive Director of ANDHealth and previously served on the Board of the Stephanie Alexander Kitchen Garden Foundation for 16 years. During 2021, Kate was recognised as one of Telstra Health’s inaugural Brilliant Women in Digital Health and named Biotech Daily’s CEO of the Year. In 2020, Kate won the Executive Leader award in the inaugural B&T Women Leading Tech Awards. She received her Bachelor of Applied Science Health Information Management degree from Latrobe University.

Chloé Argyle is the Managing Director of Éthica Capital, the equity capital markets advisory arm of GBC Group, specialising in capital markets, mergers and acquisitions, and strategic financing. With more than 15 years’ experience in capital markets, she has advised companies and investors on capital raising and strategic transactions across a broad range of sectors.

Chloé was awarded the 2025 Women in Banking and Finance Award for Achievement in Institutional, Corporate & Investment Banking and brings a practical perspective on the opportunities, capital flows, and trends shaping Australian equity markets.

Mining industry veteran with +30 years of board & executive level experience with substantial operational and financial expertise.

Sean has held a variety of operations and finance leadership positions incl. Director and CFO in mining & exploration companies across gold, coal, copper and uranium.

Sean has a broad range of experience in mining operations, mergers and acquisitions, corporate finance, hedging, and information system management implementation.

Sean has completed a Bachelor of Commerce at Curtin University and MBA at the Curtin Business School. He is aslo a Certified Practicing Accountant

Claudia is a Managing Partner at North Star Impact Funds, an investment manager that focuses exclusively on listed companies delivering measurable social or environmental impact alongside financial returns. In FY26, the fund returned +23.4%, outperforming the ASX All Ordinaries by 17.7% and the ASX Small Industrials by 24.3%. Prior to North Star, Claudia was on the investment team at Morphic Asset Management, a global ESG Hedge fund. The alpha beta separation strategy focused on global industrials primarily in the US, Japan and Europe. The fund was subsequently acquired by Ellerston Capital.

Claudia began her career at a hedge fund in Sydney before moving back to China to work in Management Consulting. In 2007, Claudia moved to Hong Kong to work for Morgan Stanley joining the Asia Equity Research Sales team. There she covered the broader Asia Pacific region with a particular focus on Hong Kong/China and Taiwan.  She was consistently ranked among the top three across both long-only and hedge fund clients. During her tenure, Morgan Stanley was consistently ranked among the top three houses in capital markets, bringing many of Asia’s largest and highest-profile companies to market, including Alibaba, AIA, Wynn Macau, and the Glencore dual listing.

Armina is co-founder and co-Portfolio Manager of Minotaur Capital Management, which leverages a tech-first, AI-led approach to investing in global equities to deliver superior risk-adjusted returns. Since inception in May 2024, Minotaur has delivered 21.7% returns pa net of fees, which is 4.2ppts ahead of its benchmark, the MSCI ACWI (net AUD). Prior to founding Minotaur, Armina was the Portfolio Manager at Grok Ventures, the family office and investment firm of Mike Cannon-Brookes, co-founder and CEO of software company, Atlassian. At Grok, Armina managed the global equities portfolio and provided input on fixed income, derivatives, infrastructure and venture capital investments. Prior to this, Armina was Senior Investment Director at Audant Investments, the family office of Robert Whyte, with a focus on global equities. Armina started her career at J.P. Morgan in 2008 in Australian Equities Research. At JPMorgan, Armina was in the Equity Strategy team, then became one of the lead analysts in the Emerging Companies sector with coverage of stocks smaller than the ASX200, focusing on the technology and consumer discretionary sectors.

Shaun McEwan is one of Asia Pacific’s most trusted voices on the corporate and gala events stage. An Australian who has called Singapore home for 15 years, Shaun is the founder and CEO of Eagle Eye Pte Ltd.

Shaun works across a diverse range of settings, including charity galas, industry conferences, business chamber events, investor summits, and professional development programs for government and global brands in the payments and luxury sectors. As an experienced MC, auctioneer, and digital platform operator for charity galas, he has helped raise over $100 million for healthcare, community, and economic development organisations across the region.

Partnering on over 75 events annually, Shaun brings more than 20 years of experience in executive leadership development, learning design, and event management to every stage. He is renowned for his ability to maintain high energy and sharp engagement throughout long, back-to-back agendas. By reading the room and expertly managing the pace, he finds the perfect balance of humor and warmth, transforming packed schedules into genuinely engaging experiences. This instinct for momentum, paired with his professional polish, is why clients return to him time and again.

Shaun holds a Bachelor of Arts from Victoria University of Technology, Melbourne, and a Certificate IV in Workplace Assessment and Training. He is a former Board Member of the Australia New Zealand Association (ANZA), a former Executive Committee Member of the Asia Professional Speakers Singapore (APSS), and a former Board Member of Jump Street Asia — reflecting a long-standing commitment to Singapore’s business and community life.

For an audience of investors, executives and dealmakers from across Asia Pacific, Shaun is the steady, energetic presence who makes a long day of presentations feel sharp, purposeful and worth staying for right through to the final session.